Issue Date: September 28, 2015
Cayman, MD Anderson In Cancer Drug Pact
Biochemicals supplier Cayman Chemical is joining with the University of Texas MD Anderson Cancer Center and Fannin Innovation Studio to form ACF Pharmaceuticals, a drug company that will pursue small-molecule inhibitors for inflammation-induced cancers such as melanoma and colon cancer. Under the pact, Cayman will develop molecules that modulate the cyclooxygenase (COX) pathway. MD Anderson will evaluate them, and Fannin, a Houston-based life science commercialization firm, will provide funding and management.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society